

IMPORTANT NEWS

Date: 12th August 2026

VaRi Bioscience GmbH Has Successfully Completed Phase IIB for VR102, a Long-Acting Estrogen-Releasing Vaginal Ring for the Local Therapy of Vulvovaginal Atrophy

Berlin, Germany, 12th August 2026 – VaRi Bioscience GmbH is a German women's health company located in the Berlin-Brandenburg cluster region, focusing on the development of innovative drugs based on its proprietary vaginal ring drug delivery technology. Together with its shareholder Aristo Pharma GmbH, VaRi Bioscience GmbH advances its pipeline of long-acting vaginal ring products.

Today VaRi Bioscience GmbH is excited to announce that it has received positive data from its Phase IIB clinical trial for VR102, a placebo-controlled, double-blind, combined dose-finding and proof-of-concept trial with parallel-group design in postmenopausal women. The purpose of the trial was the identification of a dose that improves the signs and symptoms of vulvovaginal atrophy while not increasing systemic estrogen levels beyond quantification level. Primary efficacy endpoints were improvements in objective signs of VVA, such as, e.g., maturation value (MV), superficial cells (SF), and pH. On all measures, VR102 displayed a dose-dependent and pronounced effect that achieved statistical significance, persisting over the total 3 months period of the clinical trial. In addition and after an intended 2 weeks vaginal mucosa recovery period, plasma estrogen levels constantly remained on natural levels. Efficacy was at least comparable to that of marketed products. There were no considerable SAE's, and the participating women expressed their overall high satisfaction and ring wearing comfort.

"We are proud to have achieved our goal and finalized our Phase IIB successfully, together with our partner Aristo Pharma GmbH. We are now focusing on the start of Phase III in Q1'2027", explains Klaus Nickisch, CEO of VaRi Bioscience GmbH.

Guido Zimmermann, EVP Pharmaceutical Development, Regulatory & Quality Aristo Pharma Group, stated: „We are very excited about the results which have been delivered by Phase IIB of VR102, and we are proud to have the experienced colleagues of VaRi Bioscience in our team. VR102 will offer all healthcare professionals and patients a novel and more compliant option in the treatment of VVA”.

In parallel to developing VR102, VaRi Bioscience GmbH is advancing its new-type-in-market, long-acting, non-invasive contraceptive vaginal ring, VR105. The pilot study for dose finding will be finalized in Q3'2026.

About VaRi Bioscience GmbH

VaRi Bioscience GmbH is an innovative German biotech company that is pioneering novel approaches to serve high unmet medical needs in various therapeutic areas of Female Health. The company focuses on the discovery and development of innovative products centered around its unique, IP-protected approach of novel drug delivery concepts. Please visit our website: www.vari-bioscience.com or connect with us on LinkedIn. For more Information, please contact:

Klaus Nickisch, PhD (CEO): +49 174 1510 148, knickisch@vari-bioscience.com,

Kerstin Bode-Greuel, MD, PhD (Corporate Development): +49 170 5265 883, kbode-greuel@vari-bioscience.com

Please visit our website: www.vari-bioscience.com or connect with us on LinkedIn

About Aristo Pharma GmbH

Aristo Pharma GmbH, established in 2008, is one of the fastest growing pharmaceutical companies in Europe covering most of the European markets.

As a vertically integrated company, Aristo Pharma GmbH is operating five state-of-the-art manufacturing facilities in Germany and Spain.

With its approx. 1,700 highly motivated employees and its 12 sales and marketing locations, Aristo Pharma GmbH promotes high standard pharmaceutical products and medical devices to doctors, pharmacies and wholesalers across Europe.